Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables (2016 - 2025)

China Pharma Holdings filings provide 16 years of Receivables readings, the most recent being $303696.0 for Q4 2025.

  • On a quarterly basis, Receivables fell 97.81% to $303696.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $303696.0, a 97.81% decrease, with the full-year FY2025 number at $303696.0, down 97.81% from a year prior.
  • Receivables hit $303696.0 in Q4 2025 for China Pharma Holdings, down from $355789.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $14.2 million in Q1 2024 to a low of $91753.0 in Q2 2023.
  • Median Receivables over the past 5 years was $1.2 million (2022), compared with a mean of $3.5 million.
  • Biggest five-year swings in Receivables: skyrocketed 15147.01% in 2024 and later crashed 97.81% in 2025.
  • China Pharma Holdings' Receivables stood at $2.1 million in 2021, then crashed by 78.94% to $450670.0 in 2022, then skyrocketed by 46.98% to $662392.0 in 2023, then skyrocketed by 1990.85% to $13.8 million in 2024, then crashed by 97.81% to $303696.0 in 2025.
  • The last three reported values for Receivables were $303696.0 (Q4 2025), $355789.0 (Q3 2025), and $317154.0 (Q2 2025) per Business Quant data.